BridgeBio Pharma (BBIO) Non Operating Income (2018 - 2026)

BridgeBio Pharma has disclosed Non Operating Income across 9 years of filings, most recently posting $4.3 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $4.3 million, up 106.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$324.7 million (down 18561.74% YoY), and the FY2025 annual result was -$209.1 million, down 511.77% from the prior year.
• Non Operating Income came in at $4.3 million for Q1 2026 at BridgeBio Pharma, up from -$240.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $70.3 million in Q4 2023 to a low of -$240.3 million in Q4 2025.
• The 5-year median for Non Operating Income is -$5.3 million (2023), against an average of -$17.8 million.
• Across the five-year window, Non Operating Income jumped 620.46% in 2024 and sank 7396.84% in 2025, its largest moves.
• BridgeBio Pharma's Non Operating Income stood at $39.6 million in 2022, then soared by 77.58% to $70.3 million in 2023, then plunged by 42.95% to $40.1 million in 2024, then tumbled by 698.87% to -$240.3 million in 2025, then jumped by 101.77% to $4.3 million in 2026.
• The last three Non Operating Income figures came in at $4.3 million (Q1 2026), -$240.3 million (Q4 2025), and -$41.3 million (Q3 2025), per Business Quant data.